What role will 'gliptins' play in glycemic control?

Zachary T. Bloomgarden; Andrew Drexler

doi:10.3949/ccjm.75.4.305

What role will 'gliptins' play in glycemic control?

Zachary T. Bloomgarden
, Andrew Drexler

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levels of incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.

Original language	English
Pages (from-to)	305-310
Number of pages	6
Journal	Cleveland Clinic Journal of Medicine
Volume	75
Issue number	4
DOIs	https://doi.org/10.3949/ccjm.75.4.305
State	Published - Apr 2008

Access to Document

10.3949/ccjm.75.4.305

Cite this

@article{c36b5d959da9492eb0cd91f3edaf2c06,

title = "What role will 'gliptins' play in glycemic control?",

abstract = "The gliptins, a new class of oral drugs for type 2 diabetes mellitus, lower blood glucose levels by a novel mechanism: ie, by inhibiting the enzyme dipeptidyl peptidase 4, thereby increasing the circulating levels of incretins (gut hormones that can boost insulin levels). This article reviews the current evidence on the effectiveness of gliptins and suggests several ways in which these agents could be used in diabetes treatment.",

author = "Bloomgarden, \{Zachary T.\} and Andrew Drexler",

year = "2008",

month = apr,

doi = "10.3949/ccjm.75.4.305",

language = "English",

volume = "75",

pages = "305--310",

journal = "Cleveland Clinic Journal of Medicine",

issn = "0891-1150",